Nathalie Gobeau
Overview
Explore the profile of Nathalie Gobeau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barber B, Webster R, Potter A, Llewellyn S, Sahai N, Leelasena I, et al.
Int J Antimicrob Agents
. 2024 May;
64(1):107196.
PMID: 38734217
With the spread of artemisinin resistance throughout Southeast Asia and now in Africa, the antimalarial drug pyronaridine is likely to become an increasingly important component of new antimalarial drug regimens....
2.
Abla N, Howgate E, Rowland-Yeo K, Dickins M, Bergagnini-Kolev M, Chen K, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Aug;
12(9):1335-1346.
PMID: 37587640
As part of a collaboration between Medicines for Malaria Venture (MMV), Certara UK and Monash University, physiologically-based pharmacokinetic (PBPK) models were developed for 20 antimalarials, using data obtained from standardized...
3.
Demarta-Gatsi C, Andenmatten N, Jimenez-Diaz M, Gobeau N, Cherkaoui-Rabti M, Fuchs A, et al.
Antimicrob Agents Chemother
. 2023 May;
67(6):e0157422.
PMID: 37133382
The development of new combinations of antimalarial drugs is urgently needed to prevent the spread of parasites resistant to drugs in clinical use and contribute to the control and eradication...
4.
Walz A, Duffey M, Aljayyoussi G, Sax S, Leroy D, Besson D, et al.
Pharmaceuticals (Basel)
. 2023 Apr;
16(2).
PMID: 37009844
With artemisinin-resistant parasites emerging in Africa, the need for new antimalarial chemotypes is persistently high. The ideal pharmacodynamic parameters of a candidate drug are a rapid onset of action and...
5.
Cherkaoui-Rbati M, Andenmatten N, Burgert L, Egbelowo O, Fendel R, Fornari C, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Nov;
12(1):50-61.
PMID: 36412499
Chemoprophylactics are a vital tool in the fight against malaria. They can be used to protect populations at risk, such as children younger than the age of 5 in areas...
6.
Wicha S, Walz A, Cherkaoui-Rbati M, Bundgaard N, Kuritz K, Gumpp C, et al.
Antimicrob Agents Chemother
. 2022 Oct;
66(11):e0055622.
PMID: 36197116
The development and spread of drug-resistant phenotypes substantially threaten malaria control efforts. Combination therapies have the potential to minimize the risk of resistance development but require intensive preclinical studies to...
7.
Chughlay M, Chalon S, El Gaaloul M, Gobeau N, Mohrle J, Berghmans P, et al.
Am J Trop Med Hyg
. 2022 Aug;
107(4):804-814.
PMID: 36037868
Plasmodium falciparum sporozoite (PfSPZ) direct venous inoculation (DVI) using cryopreserved, infectious PfSPZ (PfSPZ Challenge [Sanaria, Rockville, Maryland]) is an established controlled human malaria infection model. However, to evaluate new chemical...
8.
Radohery G, Walz A, Gumpp C, Cherkaoui-Rbati M, Gobeau N, Gower J, et al.
Antimicrob Agents Chemother
. 2022 Jun;
66(7):e0011422.
PMID: 35727057
The rate at which parasitemia declines in a host after treatment with an antimalarial drug is a major metric for assessment of antimalarial drug activity in preclinical models and in...
9.
Lill D, Kummel A, Mitov V, Kaschek D, Gobeau N, Schmidt H, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Feb;
11(4):512-523.
PMID: 35199969
Simulation of combination therapies is challenging due to computational complexity. Either a simple model is used to simulate the response for many combinations of concentration to generate a response surface...
10.
Murithi J, Pascal C, Bath J, Boulenc X, Gnadig N, Pasaje C, et al.
Sci Transl Med
. 2021 Jul;
13(603).
PMID: 34290058
The emergence and spread of resistance to first-line antimalarials creates an imperative to identify and develop potent preclinical candidates with distinct modes of action. Here, we report the identification of...